In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Micron Technology, Inc.
(NASDAQ:MU), Varian Medical Systems, Inc. (NYSE:VAR), St. Joe
Company (NYSE:JOE), Himax Technologies, Inc. (NASDAQ:HIMX), Aerie
Pharmaceuticals, Inc. (NASDAQ:AERI), and Hexcel Corporation
(NYSE:HXL), including updated fundamental summaries, consolidated
fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
MU DOWNLOAD: http://Capital-Review.com/register/?so=MU
VAR DOWNLOAD: http://Capital-Review.com/register/?so=VAR JOE
DOWNLOAD: http://Capital-Review.com/register/?so=JOE HIMX DOWNLOAD:
http://Capital-Review.com/register/?so=HIMX AERI DOWNLOAD:
http://Capital-Review.com/register/?so=AERI HXL DOWNLOAD:
http://Capital-Review.com/register/?so=HXL
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Micron
Technology, Inc. (NASDAQ:MU), Varian Medical Systems, Inc.
(NYSE:VAR), St. Joe Company (NYSE:JOE), Himax Technologies, Inc.
(NASDAQ:HIMX), Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), and
Hexcel Corporation (NYSE:HXL) on a fundamental level and outlines
the overall demand for their products and services in addition to
an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the
recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed February 27th, 2019. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
MICRON TECHNOLOGY, INC. (MU) REPORT
OVERVIEW
Micron Technology's Recent Financial
Performance
For the three months ended November 30th, 2018
vs November 30th, 2017, Micron Technology reported revenue of
$7,913.00MM vs $6,803.00MM (up 16.32%) and analysts estimated basic
earnings per share $2.91 vs $2.36 (up 23.31%). For the twelve
months ended August 31st, 2018 vs August 31st, 2017, Micron
Technology reported revenue of $30,391.00MM vs $20,322.00MM (up
49.55%) and analysts estimated basic earnings per share $12.27 vs
$4.67 (up 162.74%). Analysts expect earnings to be released on
March 20th, 2019. The report will be for the fiscal period ending
February 28th, 2019. The reported EPS for the same quarter last
year was $2.80. The estimated EPS forecast for the next fiscal year
is $3.52 and is expected to report on September 19th, 2019.
To read the full Micron Technology, Inc. (MU) report, download
it here:
http://Capital-Review.com/register/?so=MU
-----------------------------------------
VARIAN MEDICAL SYSTEMS, INC. (VAR) REPORT
OVERVIEW
Varian Medical's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Varian Medical reported revenue of
$741.00MM vs $678.50MM (up 9.21%) and analysts estimated basic
earnings per share $1.13 vs -$1.22. For the twelve months ended
September 30th, 2018 vs September 30th, 2017, Varian Medical
reported revenue of $2,919.10MM vs $2,619.30MM (up 11.45%) and
analysts estimated basic earnings per share $1.64 vs $2.36 (down
30.51%). Analysts expect earnings to be released on April 24th,
2019. The report will be for the fiscal period ending March 31st,
2019. Reported EPS for the same quarter last year was $1.15. The
estimated EPS forecast for the next fiscal year is $5.21 and is
expected to report on October 22nd, 2019.
To read the full Varian Medical Systems, Inc. (VAR) report,
download it here:
http://Capital-Review.com/register/?so=VAR
-----------------------------------------
ST. JOE COMPANY (JOE) REPORT OVERVIEW
St. Joe's Recent Financial Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, St. Joe reported revenue of $23.68MM vs
$33.99MM (down 30.34%) and analysts estimated basic earnings per
share $0.09 vs $0.08 (up 12.50%). For the twelve months ended
December 31st, 2017 vs December 31st, 2016, St. Joe reported
revenue of $98.80MM vs $95.74MM (up 3.19%) and analysts estimated
basic earnings per share $0.84 vs $0.21 (up 300.00%). Analysts
expect earnings to be released on March 7th, 2019. The report will
be for the fiscal period ending December 31st, 2018. Reported EPS
for the same quarter last year was -$0.08. The estimated EPS
forecast for the next fiscal year is $0.11 and is expected to
report on March 7th, 2019.
To read the full St. Joe Company (JOE) report, download it here:
http://Capital-Review.com/register/?so=JOE
-----------------------------------------
HIMAX TECHNOLOGIES, INC. (HIMX) REPORT
OVERVIEW
Himax Technologies' Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Himax Technologies reported revenue of
$188.38MM vs $197.15MM (down 4.44%) and basic earnings per share
$0.01 vs $0.02 (down 76.19%). For the twelve months ended December
31st, 2018 vs December 31st, 2017, Himax Technologies reported
revenue of $723.61MM vs $685.17MM (up 5.61%) and analysts estimated
basic earnings per share $0.05 vs $0.16 (down 68.75%). Analysts
expect earnings to be released on May 9th, 2019. The report will be
for the fiscal period ending March 31st, 2019. The reported EPS for
the same quarter last year was -$0.02.
To read the full Himax Technologies, Inc. (HIMX) report,
download it here:
http://Capital-Review.com/register/?so=HIMX
-----------------------------------------
AERIE PHARMACEUTICALS, INC. (AERI) REPORT
OVERVIEW
Aerie Pharmaceuticals' Recent Financial
Performance
Analysts expect earnings to be released on May
14th, 2019. The report will be for the fiscal period ending March
31st, 2019. The reported EPS for the same quarter last year was
-$1.05. The estimated EPS forecast for the next fiscal year is
$0.84 and is expected to report on February 24th, 2020.
To read the full Aerie Pharmaceuticals, Inc. (AERI) report,
download it here:
http://Capital-Review.com/register/?so=AERI
-----------------------------------------
HEXCEL CORPORATION (HXL) REPORT OVERVIEW
Hexcel's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Hexcel reported revenue of $561.00MM vs
$511.70MM (up 9.63%) and analysts estimated basic earnings per
share $0.78 vs $0.97 (down 19.59%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Hexcel reported revenue
of $2,189.10MM vs $1,973.30MM (up 10.94%) and analysts estimated
basic earnings per share $3.15 vs $3.13 (up 0.64%). Analysts expect
earnings to be released on April 22nd, 2019. The report will be for
the fiscal period ending March 31st, 2019. The reported EPS for the
same quarter last year was $0.68. The estimated EPS forecast for
the next fiscal year is $3.90 and is expected to report on January
22nd, 2020.
To read the full Hexcel Corporation (HXL) report, download it
here:
http://Capital-Review.com/register/?so=HXL
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Himax Technologies (NASDAQ:HIMX)
Historical Stock Chart
From Apr 2024 to May 2024
Himax Technologies (NASDAQ:HIMX)
Historical Stock Chart
From May 2023 to May 2024